trending Market Intelligence /marketintelligence/en/news-insights/trending/toMXrVo_1azv14icmN7JNw2 content esgSubNav
In This List

Advanced Oncotherapy plans to raise £10M via direct subscription

Podcast

Street Talk | Episode 94: Recessionary fears in '22 overblown, Fed could overtighten

CASE STUDY

Deep Market Intelligence Helps a Credit Union Craft a Successful Expansion Plan

Blog

Global M&A By the Numbers: Q1 2022

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Advanced Oncotherapy plans to raise £10M via direct subscription

Advanced Oncotherapy PLC plans to raise about £10 million through a direct subscription by investors.

The London-based company, which provides radiotherapy systems for cancer treatment, will issue 25 million ordinary shares at 40 pence apiece.

Advanced Oncotherapy said the fundraising is led by Paris-based multibillion pound private equity firm DNCA Finance, a unit of Natixis, which will invest £4.8 million, plus other new and existing investors.

The company intends to use the proceeds for general working capital purposes as it continues to develop its Linac Image Guided Hadron Technology system, a proton therapy system for treating cancer. The company will also use funds for software development and costs related to the testing and assembly site being set up at the U.K. government's Science and Technology Facilities Council in Daresbury.

Advanced Oncotherapy will seek stockholder approval for the shares, which will trade on the London's AIM exchange, at a general meeting to be held on Jan. 21, 2019.